---
title: "Sagimet Biosciences Inc. (SGMT.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SGMT.US.md"
symbol: "SGMT.US"
name: "Sagimet Biosciences Inc."
industry: "Biotechnology"
---

# Sagimet Biosciences Inc. (SGMT.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.sagimet.com](https://www.sagimet.com) |

## Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, an or...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.00 | 302/604 | - | - | - |
| PB | 1.45 | 130/604 | 1.94 | 1.70 | 0.78 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 8 | 80% |
| Overweight | 1 | 10% |
| Hold | 1 | 10% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.32 |
| Highest Target | 35.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/SGMT.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SGMT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SGMT.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.